Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice

Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed for the treatment of diabetes due to their antihyperglycemic activity. However, in the light of the most recent clinical studies, they are revolutionizing the approach to cardiovascular disease in patients with and without d...

Full description

Bibliographic Details
Main Authors: Arturo Cesaro, Vincenzo Acerbo, Erica Vetrano, Giovanni Signore, Gianmaria Scherillo, Francesco Paolo Rotolo, Gianantonio De Michele, Francesco Scialla, Giuseppe Raucci, Domenico Panico, Felice Gragnano, Elisabetta Moscarella, Raffaele Galiero, Alfredo Caturano, Roberto Ruggiero, Ferdinando Carlo Sasso, Paolo Calabrò
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:International Journal of Molecular Sciences
Subjects:
SGLT2 inhibitors (SGLT2i)
type 2 diabetes mellitus (T2DM)
CAD
adverse event
GUTI
Online Access:https://www.mdpi.com/1422-0067/24/9/8099

Internet

https://www.mdpi.com/1422-0067/24/9/8099

Similar Items